netFormulary
 Report : Medicines with links to NICE 02/06/2020 04:41:17

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abiraterone 08.03.04.02 Non Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Non Formulary NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 13.05.03 Restricted Use NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 10.01.03 Restricted Use NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopl
Adalimumab 10.01.03 Restricted Use NICE TA460 : Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 01.05.03 Formulary NICE TA460 : Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline / epinephrine 03.04.03 Non Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Non Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Non Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Non Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Alemtuzumab 08.02.03 Non Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Non Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177 Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Restricted Use NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary Atrial Fibrillation NICE TA275
Apixaban 02.08.02 Formulary Treatment of DVT/PE NICE TA341
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for AF
Apremilast 13.05.03 Restricted Use NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Restricted Use NICE TA433 : Apremilast for treating active psoriatic arthritis
Apremilast 13.05.03 Restricted Use NICE TA372: Apremilast for psoriatic arthritis
Aquacel Extra A5.02.04 Non Formulary NICE TA448 : Etelcalcetide for treating secondary hyperparathyroidism
Aquacel Extra A5.02.04 Non Formulary NICE TA456: Baricitinib for moderate to severe rheumatoid arthritis
Aquacel Extra A5.02.04 Non Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic Trioxide 08.01.05 Non Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Atezolizumab 08.01.05 Non Formulary NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.01.05 Non Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Non Formulary NICE TA520 : Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Avelumab 08.01.05 Non Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axitinib 08.01.05 Non Formulary NICE TA333: Axitinib for advanced renal cell carcinoma
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Basiliximab 08.02.02 Non Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Basiliximab 08.02.02 Non Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Belimumab 10.01 Non Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bisphosphonates 09.05.01.02 Non Formulary NICE TA464 : Bisphosphonates for treating osteoporos
Bivalirudin 02.08.01 Non Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Non Formulary NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03.02 Restricted Use NICE TA253: hepatitis
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA228: 1st line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bosutinib 08.01.05 Non Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Brentuximab vedotin 08.01.05 Non Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Non Formulary NICE TA478L Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Non Formulary NICE TA446 : Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brivaracetam 04.08.01 Restricted Use Brivaracetam Shared Care
Brodalumab 13.05 Non Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel 08.01.05 Non Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Restricted Use NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Restricted Use NICE TA516: Cabozantinib for treating medullary thyroid cancer
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Cangrelor 02.09 Non Formulary NICE TA351: Reducing Artherothrombotic Events
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Carfilzomib 08.01.05 Non Formulary NICE TA457 : Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Restricted Use NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Restricted Use NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD
Certolizumab Pegol 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Cetuximab 08.01.05 Non Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Non Formulary NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Ciclosporin 11.99.99.99 Restricted Use NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Restricted Use NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Formulary NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clearfilm A5.02.02 Non Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Cobimetinib 08.02.04 Non Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colecalciferol 800 units 09.06.04 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Restricted Use NICE TA459 : Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Conjugated oestrogens + Bazedoxifene 06.04.01.01 Non Formulary NICE TA443 : Obeticholic acid for treating primary biliary cholangitis
Crizotinib 08.01.05 Non Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Non Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Non Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Dabigatran 02.08.02 Formulary Atrial Fibrillation NICE TA249
Dabigatran 02.08.02 Formulary Treatment of DVT/PE NICE TA327
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Non Formulary NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib 08.01.05 Non Formulary NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Non Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.02 Non Formulary NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating Type 1 Diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Daratumumab 08.01.05 Non Formulary NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Darbepoetin Alfa 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Darbepoetin Alfa 09.01.03 Restricted Use NICE CG114: Anaemia in chronic kidney disease
Dasabuvir 05.03.03.02 Non Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Restricted Use NICE TA241: CML where treatment with imatinib has failed
Dasatinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Degarelix 08.03.04.02 Restricted Use NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Non Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance
Denosumab 06.06.02 Restricted Use NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA349: Diabetic Macular Oedema
Dimethyl fumarate 08.02.04 Restricted Use NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl fumarate 08.02.04 Restricted Use NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Docetaxel 08.01.05 Restricted Use NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Restricted Use NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Doxorubicin 08.01.02 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Doxorubicin 08.01.02 Formulary NICE TA440 : Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Dronedarone 02.03.02 Restricted Use NICE TA197: Atrial fibrillation - dronedarone
Edoxaban 02.08.02 Formulary NICE TA355
Edoxaban 02.08.02 Formulary Treatment of DVT/PE NICE TA354
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Eltrombopag 09.01.04 Restricted Use NICE TA293: Eltrombopag for treating chronic ITP
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Emtricitabine + rilpivirine + tenofovir alafenamide 05.03.01 Non Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Entecavir 05.03.03.01 Restricted Use NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Restricted Use NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 08.03.04.02 Restricted Use NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Restricted Use NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Restricted Use NICE CG108: Chronic heart failure
Epoetin alfa 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Restricted Use NICE CG114: Anaemia in chronic kidney disease
Epoetin beta 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Restricted Use NICE CG114: Anaemia in chronic kidney disease
Eribulin 08.01.05 Non Formulary NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Eribulin 08.01.05 Non Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Restricted Use NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Erlotinib 08.01.05 Restricted Use NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Etanercept 10.01.03 Restricted Use NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Restricted Use NICE TA35: Adult psoriasis
Etanercept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 13.05.03 Restricted Use NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Restricted Use NICE TA35: Adult psoriasis
Etanercept 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Restricted Use NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Everolimus 08.01.05 Non Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Non Formulary NICE TA348: Preventing Rejection in Liver Transplant
Everolimus 08.01.05 Non Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Non Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 02.12 Non Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release 06.01.02.03 Formulary NICE TA248: MR exenatide
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Non Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Non Formulary NICE YA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Gefitinib 08.01.05 Restricted Use NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gefitinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 08.01.03 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Glatiramer Acetate 08.02.04 Restricted Use NICE CG32: Glatiramer for the treatment of MS
Glecaprevir / Pibrentasvir 05.03.03.02 Restricted Use NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Golimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Restricted Use NICE TA220: psoriatic arthritis
Golimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Non Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Golimumab 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Guselkumab 13.05.03 Non Formulary NICE TA521 : Guselkumab for treating moderate to severe plaque psoriasis
Ibrutinib 08.01.05 Formulary NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 08.01.05 Formulary NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Idelalisib 08.01.05 Non Formulary NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 13.05.03 Restricted Use NICE TA134: Infliximab for psoriasis
Infliximab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Injection Device 06.01.01.03 Non Formulary NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis
Interferon Alfa 08.02.04 Restricted Use NICE TA75: Interferon Alfa - Chronic Hepatitis C
Interferon Beta 08.02.04 Non Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Non Formulary NICE TA32: Interferon Beta for MS
Ipilimumab 08.01.05 Non Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Non Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Non Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ivabradine 02.06.03 Restricted Use NICE CG126: Guidance on Stable Angina (2011)
Ixazomib 08.01.05 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Lamivudine 05.03.01 Restricted Use NICE CG165: Chronic Hepatitis B
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ledipasvir and Sofosbuvir 05.03.03.02 Non Formulary NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Ledipasvir and Sofosbuvir 05.03.03.02 Non Formulary NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C
Lenvatinib 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lesinurad 10.01.04 Non Formulary NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout
Liraglutide 06.01.02.03 Formulary NICE TA203: Diabetes (type 2) - liraglutide
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor + Ivacaftor 03.07 Non Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Mannitol inhalation 03.07 Non Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Melatonin 04.01.01 Formulary NICE Sleep Disorders in ADHD ESUOM2
Mepolizumab 03.04.02 Non Formulary NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Midostaurin 08.01.05 Non Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide: guidance
Milrinone 02.01.02 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl 02.06.04 Restricted Use NICE TA223: Intermittent claudication drugs
Naftidrofuryl 02.06.04 Restricted Use NICE CG147: Lower limb peripheral arterial disease management
Naltrexone 04.10.03 Restricted Use NICE TA115: Drug misuse - naltrexone
Naltrexone/ bupropion 04.05.01 Non Formulary Nice TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Non Formulary NICE TA127: Multiple sclerosis - natalizumab
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Nilotinib 08.01.05 Restricted Use NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nilotinib 08.01.05 Restricted Use NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Nilotinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nintedanib 03.11 Non Formulary NICE TA347: Recurrent non-small-cell lung cancer
Nintedanib 03.11 Non Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Niraparib 08.02.04 Non Formulary NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.02.04 Non Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Non Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Non Formulary NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.02.04 Non Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.04 Non Formulary NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.02.04 Non Formulary NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab 08.02.04 Non Formulary NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.02.04 Non Formulary NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Obinutuzumab 08.02.03 Non Formulary NICE TA513:Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Non Formulary NICE TA343: Obinutuzumab with chlorambucil for CLL
Obinutuzumab 08.02.03 Non Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Ofatumumab 08.02.03 Non Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.02.04 Non Formulary NICE TA381: Olaparib guidance
Omalizumab 03.04.02 Restricted Use NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Non Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Osimertinib 08.02.04 Non Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Restricted Use NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Oxcarbazepine 04.08.01 Formulary NICE Guidance
Paclitaxel 08.01.05 Restricted Use NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel 08.01.05 Restricted Use NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Non Formulary NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine
Palbociclib 08.03.04.01 Restricted Use NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Non Formulary NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Non Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Non Formulary NICE TA215: Pazopanib in renal cell cancer
Pegaspargase 08.01 Non Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Restricted Use NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Restricted Use NICE TA300: Hepatitis C - peginterferon alfa
Peginterferon Alfa 08.02.04 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Non Formulary NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Non Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Non Formulary NICE TA357: Pembrolizumab for melanoma after ipilimumab
Pembrolizumab 08.01.05 Non Formulary NICE TA447 : Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Non Formulary NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Non Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Perampanel 04.08.01 Restricted Use NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Non Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 08.01.05 Non Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 03.11 Restricted Use NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone
pirfenidone 03.11 Restricted Use NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy
Pomalidomide 08.02.04 Non Formulary NICE TA388: Pomalidomide for myeloma
Pomalidomide 08.02.04 Non Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Non Formulary NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Restricted Use NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Propranolol 04.07.04.02 Formulary BNF Migraine Prophylaxis
Propranolol 04.07.04.02 Formulary CKS Migraine
Prucalopride 01.06.07 Restricted Use NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.03.04.02 Non Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Radium-223 dichloride 08.03.04.02 Non Formulary NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Ramucirumab 08.01.05 Non Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranolazine 02.06.03 Restricted Use NICE CG126: Guidance on Stable Angina (2011)
Regorafenib 08.01.05 Restricted Use NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Restricted Use NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Non Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Non Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.03.04.01 Restricted Use NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Riluzole 04.09.03 Restricted Use NICE TA20: Motor neurone disease - riluzole
Rituximab (rheumatology) 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary Atrial Fibrillation NICE TA256
Rivaroxaban 02.08.02 Formulary Prophylaxis of VTE after total hip or total knee replacement NICE TA170
Rivaroxaban 02.08.02 Formulary Treatment of VTE NICE TA261
Rivaroxaban 02.08.02 Formulary NICE TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease NICE TA607
Roflumilast 03.03.03 Non Formulary NICE TA461 : Roflumilast for treating chronic obstructive pulmonary disease
Roflumilast 03.03.03 Non Formulary NICE TA244: Chronic obstructive pulmonary disease - roflumilast (only as part of a trial)
Romiplostim 09.01.04 Non Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Non Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05.02 Restricted Use NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources)
Sarilumab 10.01.03 Restricted Use NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Restricted Use NICE TA350: Plaque Psoriasis
Simeprevir 05.03.03.02 Restricted Use NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sofosbuvir 05.03.03.02 Restricted Use NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir and Velpatasvir 05.03.03.02 Non Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Restricted Use NICE TA188: Somatropin for growth failure in children
Sorafenib 08.01.05 Restricted Use NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sunitinib 08.01.05 Restricted Use NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Restricted Use NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Restricted Use NICE TA169: Renal cell carcinoma - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
Talimogene laherparepvec 08.01.05 Non Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Restricted Use NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Restricted Use NICE TA121: Glioma (newly diagnosed and high grade)
Temozolomide 08.01.05 Restricted Use NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Tenofovir Disproxil 05.03.01 Non Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Non Formulary NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Teriflunomide 08.02.04 Non Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Ticagrelor 02.09 Restricted Use NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tivozanib 08.01.05 Restricted Use NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Restricted Use NICE TA247:Tocilizumab in RA
Tocilizumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Restricted Use NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib citrate 10.01.03 Restricted Use NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan 06.05.02 Non Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Tolvaptan 06.05.02 Non Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Non Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Non Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Non Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Non Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Restricted Use NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Restricted Use NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab emtansine 08.01.05 Non Formulary NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan
Ustekinumab 13.05.03 Restricted Use NICE TA456 : Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Restricted Use NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopl
Ustekinumab 13.05.03 Restricted Use NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Restricted Use NICE TA340: Ustekinumab for treating active psoriatic arthritis
Varenicline 04.10.02 Restricted Use NICE TA123: Varenicline
Vedolizumab 01.05.03 Non Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vedolizumab 01.05.03 Non Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vemurafenib 08.01.05 Non Formulary NICE TA269: Vemurafenib for treating malignant melanoma
Venetoclax 08.01.05 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Verteporfin 11.08.02 Non Formulary NICE TA68: Photodynamic therapy for age related macular degeneration
Vigabatrin 04.08.01 Restricted Use NICE Guidelines Epilepsy
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 08.01.05 Non Formulary NICE TA489: Vismodegib for treating basal cell carcinoma
Vortioxetine 04.03.03 Formulary NICE TA367 - Vortioxetine for treating major depressive episodes
Zaleplon 04.01.01 Formulary NICE TA77
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia